Last week, readers were most interested in a story about the continued lack of clarity around Siemens Healthineers' diagnostics business at JP Morgan.

The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...

The company said that preliminary Q4 revenue was up 39 percent year over year and full-year 2025 revenue increased 35 percent ...

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

President and CEO Sam Raha characterized the company's pipeline of new products as "more robust than we've had in five years." ...

NEW YORK — Several Delta Dental dental health plan administrators said on Thursday that they will begin coverage of OraLiva's oral cancer test.

Chairman and CEO Adam Schechter said that deals may open up as hospital systems grow concerned about Medicaid cuts and the end of Affordable Care Act subsidies.

The CitoCBC system received FDA 510(k) clearance and CLIA waiver almost a year ago and provides results in about eight minutes in near-patient settings.

Diagnostics is already operating somewhat separately from the firm's other two business units under its new organizational structure, company officials said.

The Spanish company will use the funding to accelerate the clinical transition of its LiverAce Combo assay for drug-induced liver injury assessment.

Altai Capital said last month it had "serious concerns about the company’s significant share price underperformance." ...

In a presentation, executives discussed upcoming data readouts and their potential effect on reimbursement for the firm's FirstLook Lung test.